These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 10644281)
41. FDA drug-review, surveillance processes under scrutiny. Miller JL Am J Health Syst Pharm; 1999 Mar; 56(5):404, 406, 408. PubMed ID: 10096696 [No Abstract] [Full Text] [Related]
42. Do thiazolidinediones cause congestive heart failure? Kennedy FP Mayo Clin Proc; 2003 Sep; 78(9):1076-7. PubMed ID: 12962160 [No Abstract] [Full Text] [Related]
43. [Proper usage of thiazolidinediones]. Shimizu N Nihon Rinsho; 2000 Feb; 58(2):383-8. PubMed ID: 10707562 [TBL] [Abstract][Full Text] [Related]
44. Thiazolidinedione hepatotoxicity: a class effect? Tolman KG Int J Clin Pract Suppl; 2000 Oct; (113):29-34. PubMed ID: 11965828 [TBL] [Abstract][Full Text] [Related]
45. GSK fights compensation claims from UK patients who took rosiglitazone. Dyer C BMJ; 2013 Feb; 346():f695. PubMed ID: 23377792 [No Abstract] [Full Text] [Related]
46. Commentary on 'Case series of liver failure associated with rosiglitazone and pioglitazone' by Floyd et al. Osei SY; Koro CE; Cobitz AR; Kolatkar NS; Stender M Pharmacoepidemiol Drug Saf; 2009 Dec; 18(12):1244-6. PubMed ID: 19655316 [No Abstract] [Full Text] [Related]
47. Commentary on 'Case series of liver failure associated with rosiglitazone and pioglitazone' by James Floyd et al. Beiderbeck AB; Sakaguchi M Pharmacoepidemiol Drug Saf; 2009 Dec; 18(12):1247-9. PubMed ID: 19842093 [No Abstract] [Full Text] [Related]
49. [Rosiglitazone (BRL-49653)]. Oka Y Nihon Rinsho; 2002 Sep; 60 Suppl 9():438-41. PubMed ID: 12387030 [No Abstract] [Full Text] [Related]
50. Rosiglitazone in the management of older patients with type 2 diabetes mellitus. Kreider M; Heise M Int J Clin Pract; 2002 Sep; 56(7):538-41. PubMed ID: 12296617 [TBL] [Abstract][Full Text] [Related]
51. [The critically ill liver: hepatic ischemia]. Trujillo MH; Hernández Adrían G G E N; 1992; 46(1):61-7. PubMed ID: 1305120 [No Abstract] [Full Text] [Related]
53. Serious liver injury. Leading reason for drug removals, restrictions. Meadows M FDA Consum; 2001; 35(3):8-9. PubMed ID: 11458559 [No Abstract] [Full Text] [Related]